Otrivin Menthol

Leaflet attached to the packaging: information for the user

Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.

Otrivin Menthol, 1 mg/ml, nasal spray, solution

Xylometazoline hydrochloride

Read the leaflet carefully before using the medicine, as it contains important information for the patient.

This medicine should always be used exactly as described in the patient leaflet or as directed by a doctor, pharmacist, or nurse.

• Keep this leaflet, you may need to read it again.
• If you need advice or additional information, consult a pharmacist or nurse.
• If the patient experiences any side effects, including any possible side effects not listed in this leaflet, they should inform their doctor, pharmacist, or nurse. See section 4.
• If there is no improvement after 10 days or the patient feels worse, they should contact their doctor.

Table of contents of the leaflet:

• 1. What is Otrivin Menthol and what is it used for
• 2. Important information before using Otrivin Menthol
• 3. How to use Otrivin Menthol
• 4. Possible side effects
• 5. How to store Otrivin Menthol
• 6. Contents of the packaging and other information

1. What is Otrivin Menthol and what is it used for

The active substance of Otrivin Menthol is xylometazoline hydrochloride.
Otrivin Menthol is a locally acting decongestant that reduces nasal congestion and swelling of the nasal mucosa. It unblocks the nose, making it easier to breathe.
The medicine also contains excipients such as menthol and cineole (eucalyptol), which give a cooling sensation on the mucous membranes.
The effect of Otrivin Menthol starts within 2 minutes and lasts for up to 12 hours.
Otrivin Menthol is indicated for use in adults and adolescents over 12 years of age.
Otrivin Menthol is used for excessive nasal congestion in the common cold, hay fever, allergic rhinitis, and sinusitis.
By reducing nasal congestion, the medicine can also be used as an adjunct in the treatment of middle ear infections. Otrivin Menthol facilitates nasal examination (examination of the nasal cavity).
Otrivin Menthol does not contain preservatives.

2. Important information before using Otrivin Menthol

When not to use Otrivin Menthol:

• if the patient is allergic to xylometazoline hydrochloride or any of the other ingredients of this medicine (listed in section 6),
• if the patient has undergone surgery through the nose, e.g., removal of the pituitary gland or an operation involving exposure of the dura mater (brain surgery through the nose or mouth),
• if the patient has narrow-angle glaucoma (increased eye pressure),
• if the patient has a very dry nasal mucosa (atrophic rhinitis or dry rhinitis),
• in children under 12 years of age.

Warnings and precautions

Before using the medicine, the patient should consult a doctor, pharmacist, or nurse in the following cases:

• high blood pressure,
• heart disease (e.g., long QT syndrome),
• hyperthyroidism,
• diabetes,
• enlarged prostate,
• benign tumor of the adrenal gland that produces large amounts of adrenaline and noradrenaline (pheochromocytoma),
• taking certain antidepressant medicines known as monoamine oxidase inhibitors (MAOIs) or taking them within the last 2 weeks,
• taking tricyclic and tetracyclic antidepressants,
• like other nasal decongestants, Otrivin Menthol may cause insomnia, dizziness, tremors, heart rhythm disturbances, and increased blood pressure in sensitive patients. If such symptoms occur, the patient should consult a doctor,
• like other nasal decongestants, Otrivin Menthol should not be used for more than 10 consecutive days. If symptoms persist, the patient should consult a doctor. Using the medicine for a longer period than 10 days or in higher doses than recommended may worsen symptoms or cause them to recur.
• Otrivin Menthol should not be used in the eyes or mouth.
• A higher dose than recommended should not be used, especially in children and the elderly.

Children and adolescents

Otrivin Menthol should not be used in children under 12 years of age.

Otrivin Menthol and other medicines

The patient should inform their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Otrivin Menthol should not be used in combination with certain medicines used to treat depression. These include:

• monoamine oxidase inhibitors (MAOIs): Otrivin Menthol should not be used in combination with MAOIs or within 14 days of stopping them,
• tricyclic and tetracyclic antidepressants.

If the patient has taken any of these medicines before using Otrivin Menthol, they should consult their doctor.

Pregnancy and breastfeeding

If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor before using this medicine.
Otrivin Menthol should not be used during pregnancy.
During breastfeeding, Otrivin Menthol can be used only after consulting a doctor.

Driving and using machines

Otrivin Menthol, when used as recommended, does not affect or has a negligible effect on the ability to drive and use machines.

Otrivin Menthol contains macrogol glycerol hydroxystearate

This medicine contains 2.75 mg/ml of macrogol glycerol hydroxystearate. The medicine may cause skin reactions.

3. How to use Otrivin Menthol

This medicine should always be used exactly as described in the patient leaflet or as directed by a doctor, pharmacist, or nurse. In case of doubt, the patient should consult their doctor, pharmacist, or nurse.
Otrivin Menthol should not be used in children under 12 years of age.
Adults and adolescents over 12 years of age:
1 dose of Otrivin Menthol spray into each nostril 3 times a day. The last dose should be taken before going to bed.
Do not use more than 3 times a day into each nostril.
Otrivin Menthol should not be used for more than 10 consecutive days.

Method of administration

The medicine is intended for nasal use.
Be careful not to spray the aerosol into the eyes.

• 1. Clean the nose.
• 2. Remove the protective cap.
• 3. Do not cut the tip of the applicator.

• 4. Before the first use, press the pump 4 times. The pump will be ready for further use throughout the recommended use period. If, after full compression of the pump, the aerosol is not sprayed, or if the medicine has not been used for more than 6 days, the pump should be prepared again by pressing it 4 times. Do not spray towards the eyes or mouth.
• 5. Hold the bottle upright, supporting the base with the thumb, and place the tip between two fingers.

• 6. Tilt the head forward and insert the tip into the nostril.
• 7. Press the pump and inhale through the nose at the same time.

• 8. Repeat the steps when administering the medicine to the other nostril.
• 9. After use, clean and dry the applicator tip and replace the protective cap.

For hygiene reasons, one package of the medicine should be used by only one patient.

Using a higher dose of Otrivin Menthol than recommended

In case of using a higher dose of the medicine than recommended, the patient should immediately consult a doctor or pharmacist.
Symptoms of overdose are severe dizziness, excessive sweating, significantly lowered body temperature, headache, slow heart rate, breathing difficulties, coma, convulsions, high blood pressure (hypertension), which may be followed by hypotension.
Symptomatic treatment should be applied.

Missing a dose of Otrivin Menthol

A double dose should not be used to make up for a missed dose.
In case of any further doubts about using this medicine, the patient should consult their doctor or pharmacist.

4. Possible side effects

Like all medicines, Otrivin Menthol can cause side effects, although not everybody gets them.
The patient should STOP usingOtrivin Menthol and immediately consult a doctorif they experience any of the following side effects, which may be symptoms of an allergic reaction:

• difficulty breathing or swallowing
• swelling of the face, lips, tongue, or throat
• severe itching with red rash or blisters These symptoms are very rare (less than 1 in 10,000 patients using the medicine).

Common (may affect up to 1 in 10 people using the medicine):

dryness or irritation of the nasal mucosa, discomfort in the nose, nausea, headache, burning sensation at the site of administration.

Uncommon (may affect up to 1 in 100 people using the medicine):

nosebleeds.
Very rare (may affect less than 1 in 10,000 people using the medicine):
allergic reaction (skin rash, itching), transient vision disturbances, irregular or accelerated heart rhythm.

Reporting side effects

If the patient experiences any side effects, including any side effects not listed in the leaflet, they should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych, Al. Jerozolimskie 181C, 02-222 Warsaw, phone: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
By reporting side effects, more information can be collected on the safety of the medicine.

5. How to store Otrivin Menthol

The medicine should be stored out of sight and reach of children.
The medicine should not be used after the expiry date stated on the packaging. The expiry date refers to the last day of the month.
Do not store above 25°C.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.

6. Contents of the packaging and other information

What Otrivin Menthol contains

• The active substance of Otrivin Menthol is xylometazoline hydrochloride. One ml of solution contains 1 mg of xylometazoline hydrochloride.
• The other ingredients of the medicine are: sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, sodium chloride, disodium edetate, levomenthol, cineole (eucalyptol), sorbitol, macrogol glycerol hydroxystearate, purified water.

What Otrivin Menthol looks like and contents of the pack

Otrivin Menthol is a 10 ml bottle with an HDPE spray pump and a PP protective cap, containing a white solution with a menthol and eucalyptol scent. The spray pump allows for precise dosing of the medicine.
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.

Marketing authorization holder in Lithuania, the country of export:

Haleon Hungary Kft.
Csörsz utca 43
1124 Budapest, Hungary

Manufacturer:

Haleon Germany GmbH
Barthstraße 4
80339 Munich, Germany

Parallel importer:

InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw

Repackaged by:

InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Lithuania, the country of export:LT/1/95/0102/002
Parallel import authorization number:191/18

Date of leaflet approval: 05.02.2025

[Information about the trademark]